Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

Papatheodoridis, George; Sypsa, Vana; Dalekos, George; Yurdaydin, Cihan; Van Boemmel, Florian; Buti, Maria; Calleja, Jose; Chi, Heng; Goulis, John; Manolakopoulos, Spilios; Loglio, Alessandro; Voulgaris, Theodoros; Gatselis, Nikolaos; Keskin, Onur; Veelken, Rhea; Lopez-Gomez, Marta; Hansen, Bettina; Savvidou, Savvoula; Kourikou, Anastasia; Vlachogiannakos, John; Galanis, Kostas; İDİLMAN, RAMAZAN; Esteban, Rafael; Janssen, Harry; Berg, Thomas; Lampertico, Pietro

doi:10.1016/j.jhep.2020.01.007

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

Atıf İçin Kopyala

Papatheodoridis G. V., Sypsa V., Dalekos G. N., Yurdaydin C., Van Boemmel F., Buti M., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.72, sa.6, ss.1088-1096, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 72 Sayı: 6
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.jhep.2020.01.007
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.1088-1096
Anahtar Kelimeler: Cirrhosis, Liver stiffness, Entecavir, Tenofovir, HCC RISK SCORES, ENTECAVIR, GUIDELINES, MANAGEMENT, TENOFOVIR
Ankara Üniversitesi Adresli: Evet

Özet

Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the need for HCC surveillance in this setting.